title: [Evaluation of the DIABOBHU Observational Study].
abstract: BACKGROUND
  The authors present and analyze the outcome of DIABOBHU observational study. The work was carried out in Hungarian type 2 diabetic patients whose treatment was insufficient with oral antidiabetic agents.
  
  
  OBJECTIVE
  The safety and efficacy of glargine insulin added to oral antidiabetic therapy treatment was evaluated.
  
  
  METHODS
  Between 2008 and 2011 3955 patients were enrolled. After proper education, patients titrated the insulin dosage under self-monitoring with the help of their attending physicians. During the 26-week study period 3 visits were included. The primary endpoint was the change of HbA1c. The secondary endpoints were fasting glucose levels, dose of insulin, body weight and body mass index, satisfaction of the patients with the treatment and the incidence of hypoglycemic events.
  
  
  RESULTS
  During the study mean HbA1c decreased from 8.94% to 7.31%. Most patients achieved the glycemic goals with very low frequency of hypoglycemia. The patients did not gain weight and were satisfied with their treatment.
  
  
  CONCLUSIONS
  The authors emphasize that this treatment based on an analogue basal insulin should be considered as an effective and safe therapy.
authors.affiliation: Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókórház, Jósa András Oktatókórház IV. Belgyógyászat Nyíregyháza Szent István u. 68. 4400.
authors.forename: Zsolt
authors.initials: Z
authors.lastname: Gaál
authors.affiliation: Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókórház, Jósa András Oktatókórház IV. Belgyógyászat Nyíregyháza Szent István u. 68. 4400.
authors.forename: Zsuzsanna
authors.initials: Z
authors.lastname: Papp
authors.affiliation: Borsod-Abaúj-Zemplén Megyei Kórház és Egyetemi Oktatókórház II. Belgyógyászat Miskolc.
authors.forename: Barnabás
authors.initials: B
authors.lastname: Bakó
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000284:Administration, Oral; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D015190:Blood Glucose Self-Monitoring; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy; D004334:Drug Administration Schedule; D006442:Glycated Hemoglobin / Q000378:metabolism; D006814:Hungary; D007003:Hypoglycemia / Q000139:chemically induced / Q000517:prevention & control; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D001786:Blood Glucose; D006442:Glycated Hemoglobin; C517652:hemoglobin A1c protein, human; D007004:Hypoglycemic Agents; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting
keywords: 2-es típusú diabetes; BOT; biztonságosság; efficacy; hatékonyság; safety; type 2 diabetes mellitus